Research Article

The “CROMa” Project: A Care Pathway for Clinical Management of Patients with Bisphosphonate Exposure

Table 4

Sample distribution of CROMa patients by BRONJ presence.

BRONJ
( %)*
Healthy
( %)*
OR (95% CI)

Osteometabolic disease11 (2,2%)387 (97,8%)
Metastatic cancer17 (16,4%) 87 (83,6%)0.20 (0.11–0.33)

  for trend 28.82,

Therapy intervals
 No therapy1 (1%)92 (99%)
 <3 years7 (3,9%)172 (96,1%)0.02 (0.01–0.07)
 >3 years4 (2,7%)146 (97,3%)0.03 (0.01–0.07)
 IV < 8 infusions2 (11,8%)15 (88,2%)0.13 (0.03–0.58)
 IV > 8 infusions 14 (22,2%)49 (77,8%)0.29 (0.16–0.52)

  for trend 41.23,

Therapy regimen
 Association between methods0 (0%)17 (100%)
 IV17 (11%)138 (89%)0.12 (0.07–0.20)
 IM0 (0%)60 (100%)
 OS11 (4,1%)259 (95,9%)0.05 (0.02–0.07)

  for trend 4.31,

The percentage ( %) is not absolute but is relative to the specific field.